Source: Lobe Sciences Ltd.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) has incorporated its wholly owned Australian subsidiary to facilitate three or more clinical trials
  • Lobe Sciences Australia is partnering with iNGENu to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131
  • The company has exclusive rights to source L-130 and other related compounds for clinical trials this year and even trials investigating new clinical indications in the future
  • Lobe Sciences Ltd. (LOBE) is up 8.70 per cent, trading at C$0.125 per share at 1:10 pm ET

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.

Lobe Sciences Australia is partnering with iNGENu to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131.

The clinical trials are expected to begin late this year or early next year, depending on local regulatory approval.

The company has exclusive rights to source L-130 and other related compounds for clinical trials this year and even trials investigating new clinical indications in the future. Lobe could also earn a 43.5 per cent rebate from the Australian Federal Government’s Research and Development tax incentive program.

The company’s Chief Executive Officer, Philip J. Young, commented that the team is moving its proprietary stable psilocin products into human clinical trials on track with their business plan.”

Lobe Sciences (LOBE) is a Canadian biopharmaceutical company focused on discovering and developing psychedelic-derived medicines for neurologic and brain diseases.

Lobe Sciences Ltd. (LOBE) is up 8.70 per cent, trading at C$0.125 per share at 1:10 pm ET.


More From The Market Herald
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.

" Lumiera Health (TSXV:NHP) partners with natural health industry leader

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.